FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation

[1]  M. Menzel,et al.  Genetic Testing and Screening of Children , 2021, The International Library of Bioethics.

[2]  J. Berg,et al.  An Age-Based Framework for Evaluating Genome-Scale Sequencing Results in Newborn Screening. , 2019, The Journal of pediatrics.

[3]  Matthew S. Lebo,et al.  Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. , 2019, American journal of human genetics.

[4]  R. Green,et al.  Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project , 2019, Pediatrics.

[5]  Yun Yen,et al.  FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine , 2018, npj Genomic Medicine.

[6]  J. Berg,et al.  Evaluating parents’ decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol , 2018, Trials.

[7]  Cristina Has,et al.  Faculty of 1000 evaluation for Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. , 2018 .

[8]  Laurie D. Smith,et al.  The NSIGHT1-randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants , 2017, npj Genomic Medicine.

[9]  J. Berg,et al.  Genetic screening: birthright or earned with age? , 2017, Expert review of molecular diagnostics.

[10]  Tiina K. Urv,et al.  Newborn Sequencing in Genomic Medicine and Public Health , 2017, Pediatrics.

[11]  Jefferey Chen,et al.  Sanger Confirmation Is Required to Achieve Optimal Sensitivity and Specificity in Next-Generation Sequencing Panel Testing. , 2016, The Journal of molecular diagnostics : JMD.

[12]  J. Mullikin,et al.  Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. , 2016, Clinical chemistry.

[13]  J. Berg,et al.  Supporting Parental Decisions About Genomic Sequencing for Newborn Screening: The NC NEXUS Decision Aid , 2016, Pediatrics.

[14]  Laurie D. Smith,et al.  A 26-hour system of highly sensitive whole genome sequencing for emergency management of genetic diseases , 2015, Genome Medicine.

[15]  B. Evans.  The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing. , 2015, Food and drug law journal.

[16]  Laurie D. Smith,et al.  Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings. , 2015, The Lancet. Respiratory medicine.

[17]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[18]  Michael S Watson,et al.  Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine. , 2015, JAMA.

[19]  J. Sharfstein.  FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science. , 2015, JAMA.

[20]  Xuan Yuan,et al.  Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders , 2014, Science Translational Medicine.

[21]  A. McGuire,et al.  Development of the clinical next-generation sequencing industry in a shifting policy climate , 2014, Nature Biotechnology.

[22]  Eric Vilain,et al.  Assessing the necessity of confirmatory testing for exome sequencing results in a clinical molecular diagnostic laboratory , 2014, Genetics in Medicine.

[23]  Neil A. Miller,et al.  Molecular diagnosis of infantile onset inflammatory bowel disease by exome sequencing. , 2013, Genomics.

[24]  Neil A. Miller,et al.  Structured Genome-Scale Variant and Clinical Data Reporting for Meta-Analysis in an Era of Genomic Medicine , 2013 .

[25]  R. Sharp,et al.  Ethical and Policy Issues in Genetic Testing and Screening of Children , 2016, Pediatric Clinical Practice Guidelines & Policies.

[26]  Peter Saffrey,et al.  Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units , 2012, Science Translational Medicine.

[27]  Marc S. Williams,et al.  US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society. , 2008, Personalized medicine.

[28]  W. Trochim,et al.  Systems thinking to improve the public's health. , 2008, American journal of preventive medicine.

[29]  W. Trochim,et al.  Practical challenges of systems thinking and modeling in public health. , 2006, American journal of public health.

[30]  B. Wilfond,et al.  Ethical issues with genetic testing in pediatrics. , 2013, Pediatrics.

[31]  Gregg Pratt,et al.  DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 1998 .

[32]  Robert Kevin Grigsby,et al.  Federal Policy for the Protection of Human Subjects , 1993, Research on social work practice.